CEBPA and myeloid neoplasm: Over the years, new molecular markers have been discovered and some of them, like mutations in fms-related tyrosine kinase-3 (FLT3), nucleophosmin 1 (NPM1), CCAAT/enhancer binding protein alpha (CEBPA) gene and runt-related transcription factor 1 (RUNX1) gene, have been included into the revised World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia, and European LeukemiaNet (ELN) risk classification system [1,2].